Health-related quality of life in robotic versus open radical prostatectomy

Stacy Rush, MSc. Eng.;* Shabbir M.H. Alibhai, MD, FRCPC;† Lizhen Xu, PhD;‡ Wei Xu, PhD;§ Alyssa S. Louis, BSc;* Andrew G. Matthew, PhD, C. Psych.;* Michael Nesbitt, BA;* Antonio Finelli, MD, FRCSC;* Neil E. Fleshner, MD, FRCSC;* Robert J. Hamilton, MD, FRCSC;* Girish Kulkarni, MD;* Alexandre Zlotta, MD, FRCSC;* Michael A.S. Jewett, MD, FRSCS;* John Trachtenberg, MD, FRCSC*

*Department of Surgery (Urology) and Oncology, Princess Margaret Cancer Centre, University Health Network and the Department of Surgery, University of Toronto, Toronto, ON; †Department of Medicine, University Health Network and the Department of Medicine, University of Toronto, Toronto, ON; ‡Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON; §Department of Surgical Oncology and Psychosocial Oncology, Princess Margaret Cancer Centre, University Health Network and the Department of Surgery and Psychiatry, University of Toronto, Toronto, ON

See related article on page 188.

Cite as: *Can Urol Assoc J* 2015;9(5-6):179-87. <http://dx.doi.org/10.5489/cuaj.2618>
Published online June 15, 2015.

Abstract

Introduction: It is unclear whether health-related quality of life (HRQoL) outcomes are superior in robot-assisted radical prostatectomy (RARP) compared to open prostatectomy (ORP).

Methods: We retrospectively analyzed records from men who received ORP or RARP at our institution between January 2009 and December 2012. Patients completed a demographics questionnaire and the Patient-Oriented Prostate Utility Scale (PORPUS), a validated disease-specific HRQoL instrument prior to surgery and every 3 months up to 15 months after surgery.

Results: In total, 974 men met the inclusion criteria (643 ORP and 331 RARP patients). At baseline, RARP patients were significantly younger ($p < 0.001$), had lower body mass index (BMI) ($p < 0.001$), lower preoperative prostate-specific antigen (PSA) ($p < 0.001$), fewer comorbidities ($p < 0.004$), and higher baseline PORPUS scores ($p = 0.024$). On follow-up, unadjusted PORPUS scores were significantly higher in the RARP group at each point. On multivariable analysis adjusting for age, ORP versus RARP procedure, Gleason score, BMI, first PSA, comorbidity, ethnicity, and baseline PORPUS scores, PORPUS score was higher for the RARP group at 3 months ($p = 0.038$) and 9 months ($p = 0.037$), but not at 6, 12, and 15 months ($p = 0.014$). No difference met pre-defined thresholds of clinical significance.

Conclusions: Though unadjusted HRQoL outcomes appeared improved with RARP compared to ORP differences, adjusted differences were seen at only 2 of 5 postoperative time points, and did not meet pre-defined thresholds of clinical significance. Further randomized trials are needed to assess whether one treatment option provides consistently better HRQoL outcomes.

Introduction

Prostate cancer is the most common solid organ tumour in North American men, with an estimated 233 000 diagnoses expected in 2014 in the United States alone.¹ Prostate-specific antigen (PSA) testing has facilitated increased early detection of locally confined tumours that are amenable to surgery. In an attempt to decrease the morbidity of open surgery, minimally invasive laparoscopic approaches were developed. Robot-assisted laparoscopic prostatectomy (RARP) has become a widely used and increasingly adopted approach. Multiple case series of RARP by experienced surgeons have suggested short-term benefits over historical controls of open radical prostatectomy (ORP) in terms of better visualization of the surgical field, lower perioperative complication rate, lower stricture rate, fewer transfusions, and shorter hospital stay.² Indeed, many surgical proponents have unequivocally stated that RARP is the sole standard of care for localized prostate cancer; however, whether health-related quality of life (HRQoL) outcomes are superior to ORP remains unclear.³⁻⁵

Major determinants of HRQoL following prostate cancer treatment include long-term side effects of sexual and urinary dysfunction. Comparisons of continence between ORP and RARP are mixed, with demonstration of no significant difference at 3 months following surgery in some cases,² faster return to continence with RARP in other cases (16 vs. 46 days),⁶ and no significant difference at the 1-year mark.⁷ International Prostate Symptom Scores (IPSS) have been demonstrably better at 1 and 3 months postoperatively with RARP.⁶ Further, sexual function may return more rapidly after RARP compared to ORP.⁸ However, limitations of previous studies are numerous and include non-randomized, uncontrolled, small, and unbalanced single surgeon case series.

To our knowledge, broader HRQoL outcomes between ORP and RARP have not yet been compared. However, general QoL measures, such as the Medical Outcomes Study SF-36, may not be sensitive to prostate-specific HRQoL outcomes. The Patient-Oriented Prostate Utility Scale (PORPUS) is a validated, sensitive, and specific tool consisting of 10 independent QoL domains that is aggregated as a psychometric score. The PORPUS is highly responsive to small changes not otherwise detected in general (non-prostate cancer-specific) tools.⁹

We sought to quantify global differences in prostate-specific HRQoL outcomes after RARP and ORP using the PORPUS and to compare our surgical outcomes in the 2 most-quoted treatment-specific domains, potency and voiding function, using the International Index of Erectile Function (IIEF)¹⁰ and IPSS, respectively.¹¹ Our secondary objective was to measure baseline differences between the two cohorts to better understand the rationale for surgical selection between treatment groups.

Methods

Patients

After receiving institutional ethics review board approval (University Health Network IRB Study ID number: 13-6495), we retrospectively analyzed the records of men consecutively treated with RP at the University Health Network in Toronto, Canada between January 2009 and December 2012. Five experienced high volume, single academic centre-based surgeons performed the ORPs and 4 of those same 5 surgeons performed the RARPs. We conducted a sensitivity analysis for the 327 RARP operations (after excluding 4 operations with unknown surgeons) to account for physician learning curve for the RARP. We fitted a linear mixed effect model to investigate whether changes of PORPUS-P over time (3, 6, 9, 12, and 15 months) are significantly different between the two groups, one for RARPs that are the first 50 operations by a surgeon and the other for those after the 50th surgery. A surgeon specific effect (random effect) is included in the model to capture the possible correlations within the operations performed by a same surgeon. No statistical significances of difference in the change of PORPUS-P between the two groups are detected ($p > 0.3$). The first 50 cases for each surgeon were included in our subsequent analysis.

Men were administered HRQoL, IIEF and IPSS questionnaires at the baseline visit at our centre (preoperatively) and at each follow-up visit, which were manually entered alongside clinical and laboratory variables into our institutional Prostate Centre Database. Baseline demographic data included age, marital status, ethnicity, smoking, and alcohol consumption. Clinical data included body mass index (BMI),

biopsy Gleason score, clinical stage, and modified Charlson comorbidity index score.¹² Surgical data included type of surgery and nerve-sparing status.

Men were included in our study if they were treated with ORP or RARP. Men were excluded if they received neoadjuvant, adjuvant, or salvage treatments.

To ensure that any missing data was missing at random, we conducted a non-parametric paired test (Wilcoxon signed rank test) and determined that the difference in the percentage of missing between ORP and RARP groups was not significant over the whole time frame ($p = 0.094$). Therefore, the missing data were not significantly skewed to one or the other surgical approaches and it is safe to assume that the missing is at random.

Outcome measures

We measured HRQoL using the PORPUS, a 10-domain multi-attribute health classification system that measures a patient's physical and emotional status (Appendix).⁴ Each domain contains 4 to 5 possible ordinal responses. Domain scores are weighted equally and normalized to provide a score from 0 to 100, where 100 indicates greatest and 0 the lowest HRQoL status (the PORPUS-P [psychometric]).^{9,13,14} The minimum clinically important difference for the PORPUS-P is 5 points.² At each time point, patients also filled out the IIEF¹⁰ and the IPSS.¹⁵ The minimum clinically important difference for IIEF and IPSS were 4 and 6 points, respectively.¹⁶ However, the minimum clinically important difference for the IIEF varied according to erectile dysfunction severity (mild: 2; moderate: 5; severe: 7).¹⁶

Data analysis

Survey data were grouped based on time of collection after surgery: 3 ± 1.5 months, 6 ± 1.5 months, 9 ± 1.5 months, 12 ± 1.5 months and 15 ± 1.5 months.

Baseline demographic characteristics were described using mean (standard deviation), and median (minimum, maximum) for quantitative variables, and proportions for categorical variables. We compared differences in baseline characteristics between the open and robotic groups using independent two-sample (unpaired) t-tests for the quantitative variables and Pearson's Chi-squared Test for the categorical data. We then conducted analyses to compare differences in the HRQoL outcomes at baseline and the follow-up times (3, 6, 9, 12 and 15 months), again using two-sample t-tests. Similar comparisons were also applied to the differences of changes of the HRQoL measure from the baseline at the various follow-up times between the open and robotic groups. We constructed univariate and multivariable linear regression models at 3, 6, 9, 12 and 15 months to examine possible predictors of the changes of HRQoL outcomes. We considered the following

predictors: age, type of operation (open vs. robotic), nerve-sparing, Gleason score, BMI, first PSA, Charlson score (0 vs. ≥ 1), ethnicity (Caucasian vs. non-Caucasian), surgeon, and baseline PORPUS. For comparison purposes, we conducted univariate analysis for IIEF and IPSS scores. A p value of 0.05 was used to denote statistical significance. All statistical analyses were done using R version 2.15.1.

Results

Baseline characteristics

A total of 974 men met the inclusion criteria, 643 in the ORP cohort, and 331 in the RARP group. The RARP group was significantly younger, more ethnically diverse, with lower BMI, less comorbidity and lower preoperative PSA compared to the ORP group (all $p < 0.05$). No significant differences were detected in marital status, smoking, alcohol consumption, or clinical stage between groups. Nerve-sparing surgery was significantly more commonly performed in the RARP group compared to the ORP group ($p < 0.001$) (Table 1).

PORPUS-P Scores

At baseline, unadjusted PORPUS-P scores were significantly higher in the RARP group compared to the ORP group (83 ± 11 ORP, 85 ± 11 RARP, $p = 0.024$). The RARP group had higher scores at every subsequent time point: 3 months (67 ± 12.5 ORP, 70 ± 13 RARP, $p = 0.007$), 6 months (74

± 12 ORP, 77 ± 10 , $p \leq 0.001$), 9 months (75 ± 12 ORP, 79 ± 11 RARP, $p < 0.001$), 12 months (76 ± 13 ORP, 82 ± 10 RARP, $p < 0.001$), and 15 months (75 ± 13 ORP, 80 ± 12 RARP, $p = 0.014$) (Fig. 1). However, none of the between-group differences were greater than 5 points at any time point, indicating no clinically significant difference between groups.¹⁷

Predictors of baseline HRQOL

On univariate analysis, increased age, higher Gleason score, higher BMI, and higher PSA level were associated with decreased PORPUS-P scores at baseline (preoperatively) ($p < 0.05$) (Table 2).

Predictors of HRQOL over time

On multivariate analysis, type of RP had a significant effect on PORPUS-P at the 3-month period after adjusting for other predictors ($p = 0.038$). The mean difference between RARP and ORP was 3.262 points. Type of RP also had a significant effect at the 9-month period after adjusting for other predictors ($p = 0.037$ mean difference 3.78 points) (Table 3). Type of RP did not have a significant effect at 6, 12, or 15 months. None of these differences met previously defined thresholds of clinical significance.

IIEF scores

We illustrated the trends in mean ($\pm$ standard deviation) IIEF scores (the IIEF-5 score is the sum of the ordinal responses to the 5 items: (1) 22-25: No erectile dysfunction; (2) 17-21:

Table 1. Baseline demographics of study patients

Factors		Open	Robotic	p value
Age, years	N	643	331	<0.001
	Mean (SD)	61.49 (7.07)	59.71 (7.03)	
First elevated PSA	N	432	195	<0.001
	Mean (SD)	7.58 (5.22)	5.89 (3.28)	
BMI	N	597	299	<0.001
	Mean (SD)	28.6 (4.0)	27.3 (3.6)	
	Non response rate	7.2%	9.7%	
CCS*	0	512 (80)	289 (87)	0.004
	≥ 1	131 (20)	42 (13)	
Biopsy Gleason score N (%)**	Low/intermediate risk: Gleason 4, 5, 6, or 7	532 (88)	310 (99)	<0.001
	High risk: Gleason 8, 9, 10	76 (12)	4 (1)	
	Caucasian: n(%)	228 (75)	98 (63)	0.008
Ethnicity***	Non-Caucasian: n(%)	75 (25)	58 (37)	
PORPUS-P score	N	437	210	0.024
	Mean (sd)	82.59 (11.10)	84.73(11.26)	
	None: n (%)	155 (25)	19 (7)	<0.001
Nerve-sparing status	Unilateral: n (%)	146 (23)	45 (15)	
	Bilateral: n (%)	326 (52)	224 (78)	

Data are shown only for statistically significantly different characteristics. PORPUS-P: Patient-Oriented Prostate Utility Scale-Psychometric; PSA: prostate-specific antigen; CCS: Charlson comorbidity score; SD: standard deviation; RARP: robot-assisted radical prostatectomy; ORP: open radical prostatectomy.

*All Charlson comorbidities are not captured in the PCDB. The following are captured: myocardial infarction, congestive heart failure, peripheral vascular disease, liver disease, diabetes mellitus, leukemia, lymphoma, AIDS, cerebrovascular Disease, dementia, pulmonary disease, rheumatologic disease, and peptic ulcer. **Missing biopsy Gleason scores: n = 35 ORP, n = 17 RARP. ***Missing ethnicity: n = 340 ORP, n = 175 RARP.

Table 2. Univariate predictors of baseline (preoperative) PORPUS-P

Variable	Effect	Confidence interval	p value
Age	-0.22	(-0.34, -0.105)	<0.001
Type of RP*	2.14	(0.30, 3.98)	0.023
Gleason score	-4.35	(-7.33, -1.37)	0.004
BMI	-0.025	(-0.26, 0.21)	0.836
First positive PSA	-0.24	(-0.44, -0.04)	0.017

*Robot-assisted radical prostatectomy compared to open radical prostatectomy. RP: radical prostatectomy; BMI: body mass index; PSA: prostate-specific antigen; PORPUS-P: Patient-Oriented Prostate Utility Scale-Psychometric.

Mild erectile dysfunction; (3) 12-16: Mild to moderate erectile dysfunction; (4) 8-11: Moderate erectile dysfunction; and (5) 5-7: Severe erectile dysfunction) over time for the RARP and ORP (Fig. 2). IIEF scores were not significantly different between groups at baseline. They were significantly higher in the RARP group at 3 months (7 ± 4 ORP, 9 ± 6 RARP, $p = 0.001$) and 12 months (10 ± 6 ORP, 12 ± 7 RARP, $p = 0.011$), although none of the differences were clinically significant (i.e., all were smaller than the minimum clinically important difference).

IPSS Scores

We illustrated the trends in mean ($\pm$ standard deviation) IPSS scores (IPSS score categories: (1) 1-7: Mild; (2) 8-19: Moderate; and (3) 20-35: Severe) over time for the RARP

Fig. 1. Psychometric PORPUS-scores (mean and standard deviation) at each time point. Baseline questionnaires plotted at month 0. The response rate for the completed PORPUS-P scores at each time point was: baseline ($n = 437$ ORP, $n = 210$ RARP), 3 months ($n = 399$ ORP, $n = 230$ RARP), 6 months ($n = 342$ ORP, $n = 208$ RARP), 9 months ($n = 236$ ORP, $n = 164$ RARP), 12 months ($n = 223$ ORP, $n = 133$ RARP), 15 months ($n = 101$ ORP, $n = 63$ RARP). Differences between RARP and ORP groups were statistically but not clinically significant at each time point (statistical significance indicated by the asterisk in the figure). PORPUS-P: Patient-Oriented Prostate Utility Scale-Psychometric; RARP: robot-assisted radical prostatectomy; ORP: open radical prostatectomy.

Table 3. Univariate analysis of changes to PORPUS-P

Month	Variable	Effect	p value
3	Type of RP	2.864	0.017
6	Type of RP	2.723	0.012
9	Type of RP	3.425	0.011
	Age	-0.202	0.032
12	Type of RP	3.616	0.009
	BMI	-0.435	0.015
15	First Detectable PSA	-0.388	0.04

Data are reported for significant variables only ($p < 0.05$). PORPUS-P: Patient-Oriented Prostate Utility Scale-Psychometric; RP: radical prostatectomy; BMI: body mass index; PSA: prostate-specific antigen.

and ORP (Fig. 3). IPSS scores were not significantly different between groups at baseline. IPSS scores were statistically significantly lower in RARP patients compared to ORP patients at 3 months (11 ± 7 ORP, 9 ± 6 RARP, $p = 0.04$), 6 months (8 ± 6 ORP, 6 ± 5 RARP, $p < 0.001$), 9 months (7 ± 6 ORP, 6 ± 5 RARP, $p = 0.007$), and 12 months (7 ± 6 ORP, 5 ± 5 RARP, $p = 0.02$), but not at 15 months. However, none of the differences were clinically significant.

Discussion

What drives technical innovation in surgery? The objective of any surgical intervention is to eliminate disease with minimal operative morbidity and without persistent detrimental effects in HRQoL. RP was historically associated with significant HRQoL losses (impotence, incontinence, bowel injury) and had been largely abandoned to radiation therapy until the anatomical prostatectomy with the possibility of

Fig. 2. Mean ($\pm$ standard deviation) IIEF scores at each time point. Baseline scores plotted at month 0. The response rate for the completed IIEF questionnaires at each time point was: baseline ($n = 364$ ORP, $n = 187$ RARP), 3 months ($n = 219$ ORP, $n = 148$ RARP), 6 months ($n = 213$ ORP, $n = 148$ RARP), 9 months ($n = 163$ ORP, $n = 121$ RARP), 12 months ($n = 154$ ORP, $n = 100$ RARP), 15 months ($n = 66$ ORP, $n = 46$ RARP). Differences between RARP and ORP groups were statistically significant at 3 months ($p < 0.001$) and 12 months ($p = 0.011$), but not clinically significant at any time point. Asterisks denote statistical significance. RARP: robot-assisted radical prostatectomy; ORP: open radical prostatectomy; IIEF: International Index of Erectile Function.

Table 4. Multivariate model for significant, but not clinically significant data predicting change in PORPUS-P scores

Time period	Variable	Effect	Confidence interval	p value
Baseline to 3 months (n = 280)	Age	-0.015	(-0.202,0.173)	0.879
	Type of RP	3.262	(0.176,6.348)	0.038
	Gleason Score	0.753	(-4.574,6.08)	0.781
	Charlson Count	1.565	(-1.41,4.541)	0.301
	Ethnicity	-4.047	(-6.998,-1.096)	0.007
	Nerve sparing 1*	1.078	(-3.395,5.551)	0.635
	Nerve sparing 2*	1.992	(-2.059,6.042)	0.334
	Nerve sparing 3*	2.567	(-3.991,9.125)	0.442
	Surgeon 2	-0.396	(-3.866,3.074)	0.822
	Surgeon 3	-6.666	(-15.892,2.56)	0.156
	Surgeon 4	-8.096	(-23.78,7.588)	0.31
	Surgeon 5	-0.991	(-4.53,2.548)	0.582
	Surgeon 6	-0.458	(-22.305,21.389)	0.967
	PORPUS-P	-0.376	(-0.503,-0.25)	0
Baseline to 6 months (n = 234)	Age	0.055	(-0.12,0.231)	0.535
	Type of RP	2.031	(-0.84,4.902)	0.165
	Gleason score	-1.015	(-6.229,4.199)	0.702
	Charlson count	1.665	(-1.201,4.532)	0.253
	Ethnicity	-1.439	(-4.203,1.326)	0.306
	Nerve sparing 1*	4.768	(0.52,9.017)	0.028
	Nerve sparing 2*	5.067	(1.031,9.102)	0.014
	Nerve sparing 3*	3.766	(-2.134,9.667)	0.21
	Surgeon 2	-3.501	(-6.716,-0.287)	0.033
	Surgeon 3	-12.564	(-22.215,-2.914)	0.011
	Surgeon 4	-14.589	(-28.121,-1.057)	0.035
	Surgeon 5	-1.759	(-4.973,1.456)	0.282
	PORPUS-P	-0.455	(-0.571,-0.338)	0
Baseline to 9 months (n = 165)	Age	-0.131	(-0.362,0.099)	0.262
	Type of RP	3.78	(0.225,7.335)	0.037
	Gleason score	7.061	(0.147,13.975)	0.045
	Charlson count	2.024	(-1.678,5.727)	0.282
	Ethnicity	-1.483	(-5.18,2.214)	0.429
	Nerve sparing 1*	1.009	(-4.695,6.713)	0.727
	Nerve sparing 2*	4.374	(-0.655,9.403)	0.088
	Nerve sparing 3*	5.298	(-3.527,14.123)	0.237
	Surgeon 2	-0.385	(-4.141,3.372)	0.84
	Surgeon 3	-2.036	(-16.564,12.491)	0.782
	Surgeon 4	3.874	(-10.713,18.461)	0.601
	Surgeon 5	-2.737	(-6.898,1.423)	0.196
	Surgeon 6	2.367	(-18.622,23.356)	0.824
	PORPUS-P	-0.466	(-0.605,-0.327)	0

**Unilateral": Nerve sparing 1; "Bilateral": Nerve sparing 2; "Unknown": Nerve sparing 3. PORPUS-P: Patient-Oriented Prostate Utility Scale-Psychometric.

potency sparing nerve-sparing technology was introduced and popularized by Walsh.¹⁸

However, in spite of the popularization of the anatomic nerve-sparing operation and its increasing use by many, many studies suggest that the quoted almost perfect continence and potency rates were either a result of routine selection bias of younger, thinner, more potent men for the operation. At most academic and community medical cen-

tres where similar procedures were performed by experienced high volume cancer surgeons, these outcomes were routinely inferior to the results claimed by the few "masters" of this operation, or perhaps these masters of the procedure really had developed superior technique. The advent of the Intuitive Surgery I robot suggested a leveling of differences because of its many unique attributes. The daVinci robot's unique dual camera system gave the surgeon the ability to

Table 4 (cont'd). Multivariate model for significant, but not clinically significant data predicting change in PORPUS-P scores

Time period	Variable	Effect	Confidence interval	p value
Baseline to 12 months (n = 139)	Age	-0.106	(-0.365,0.154)	0.422
	Type of RP	1.307	(-2.995,5.609)	0.549
	Gleason score 1	0.08	(-6.588,6.749)	0.981
	Charlson count 1	0.989	(-2.956,4.933)	0.621
	Ethnicity	-0.918	(-5.112,3.276)	0.666
	Sparing recorded 1*	0.102	(-5.732,5.936)	0.972
	Sparing recoded 2*	3.807	(-1.77,9.385)	0.179
	Sparing recoded 3*	1.551	(-14.124,17.226)	0.845
	Surgeon 2	-0.247	(-4.72,4.226)	0.913
	Surgeon 3	-16.003	(-31.314,-0.693)	0.041
	Surgeon 5	-4.893	(-9.744,-0.042)	0.048
Baseline to 15 months (n = 68)	PORPUS-P	-0.251	(-0.414,-0.087)	0.003
	Age	-0.067	(-0.457,0.323)	0.732
	Type of RP	4.706	(-1.478,10.889)	0.133
	Gleason score	6.033	(-5.955,18.021)	0.318
	Charlson count	-1.062	(-8.758,6.635)	0.783
	Ethnicity	-5.399	(-11.546,0.748)	0.084
	Nerve sparing 1*	-3.078	(-13.239,7.083)	0.546
	Nerve sparing 2*	-5.133	(-15.033,4.768)	0.303
	Nerve sparing 3*	-19.707	(-44.364,4.95)	0.115
	Surgeon 2	2.296	(-5.116,9.708)	0.537
	Surgeon 3	4.39	(-10.772,19.552)	0.564
	Surgeon 5	-0.574	(-7.741,6.592)	0.873
	PORPUS-P	-0.342	(-0.611,-0.072)	0.014

*"Unilateral": Nerve sparing 1; "Bilateral": Nerve sparing 2; "Unknown": Nerve sparing 3. PORPUS-P: Patient-Oriented Prostate Utility Scale-Psychometric.

work in a familiar visual environment – direct 3-dimensional vision with real depth of field. Furthermore, the robotic system placed the surgeon, away from the patient, seated in a comfortable, ergonomically designed console area where his fingers and feet were attached in a master slave manner where each movement of the surgeon fingers would cause scaled, tremor-reduced emulated movements to the miniature tools that were placed through traditional laparoscopic ports. The miniaturized tool's articulated wrist offered six degrees of freedom of movement. These and other unique features allowing for a visualized technically perfect urethral anastomosis. Further, the device's variable magnification, multiple working arms, and positive pressure environment suggested a blood-free operative field leading to the possibility of markedly improved results by every surgeon in performing a difficult, often bloody dissection of the neurovascular bundles. Indeed, the initial published results for RARP suggested exactly that, and the plethora of superb case series by the pioneers in robotic surgery suggested it was true.¹⁹

To attempt to understand whether these initially reported results with RARP were due to selection bias or a truly superior surgical technique, we examined whether HRQoL outcomes differed between RARP and ORP among experienced uro-oncologic surgeons. We found that disease-specific HRQoL, as measured by the PORPUS, was statistically

better after RARP compared to ORP at all 5 time points examined between 3 months and 15 months after surgery. However, these differences persisted at only 3 and 9 months after adjusting for baseline differences. Moreover, none of the differences in HRQoL between RARP and ORP groups were clinically important based on the patient's ability to perceive a meaningful difference at any time point after surgery (i.e. the minimum clinically important difference). Similar trends were noted using both the IIEF and IPSS to measure erectile function and urinary function, respectively. Again, for both latter measures, none of the differences were clinically important based on the minimum clinically important difference for each measure.

Baseline demographic differences may have contributed to the difference in QoL outcomes in ORP versus RARP. At our centre, younger males with lower BMI, Gleason scores, and total PSA, and men with less comorbidity tended to choose or be selected for RARP. Given the relatively small differences in adjusted HRQoL over time between groups, unmeasured baseline differences between the two groups may still be a factor in the differences postoperatively.

Numerous studies have measured quality of life after ORP and RARP with mixed results.^{3-5,20,21} Selection bias has been a factor in previous QoL studies comparing these procedures, where surgeons would limit their RARP patients to younger

Fig. 3. Mean ($\pm$ standard deviation) IPSS scores at each time point. Baseline scores plotted at month 0. The response rate for the completed IPSS questionnaires at each time point was: baseline ($n = 431$ ORP, $n = 213$ RARP), 3 months ($n = 382$ ORP, $n = 215$ RARP), 6 months ($n = 326$ ORP, $n = 201$ RARP), 9 months ($n = 228$ ORP, $n = 161$ RARP), 12 months ($n = 222$ ORP, $n = 135$ RARP), 15 months ($n = 101$ ORP, $n = 60$ RARP). Differences between RARP and ORP groups were statistically significant at 3 months ($p = 0.04$), 6 months ($p < 0.001$), 9 months ($p = 0.007$) and 12 months ($p = 0.02$), but not clinically significant at any time point. Asterisks denote statistical significance. RARP: robot-assisted radical prostatectomy; ORP: open radical prostatectomy; IIEF: International Index of Erectile Function; IPSS: International Prostate Symptom Scores.

groups, lower-grade tumours, or those lacking comorbidities.⁴ This phenomenon might be then considered appropriate clinical practice if RARP had been demonstrated in a convincing fashion to unequivocally better preserve potency than ORP because of its better visualization of the nerve bundles. Further, older patients with waning potency, a higher BMI and a higher volume of disease would appropriately have a higher likelihood of having their nerve bundles sacrificed for oncological efficacy in ORP.

In our experience, patients are often told that their quality of life will return to normal shortly after surgery. Our data indicate that this is not the case for most men. HRQoL did not return to normal (preoperative) levels throughout the 15-month follow-up period. Patient regret after surgery is documented in those who underwent RARP, possibly due to inflated expectations. In one study, patients were more likely to experience regret after RARP compared to ORP.²²

Our results need to be interpreted in the light of several limitations. The follow-up questionnaire response rate decreased over time. Patients who felt well may have neglected to attend later appointments to avoid wasting their time. This may introduce selection bias among respondents at later time points, and artificially lower overall HRQoL scores. However, the converse may also be true in that patients who were discouraged by their HRQoL outcomes or suffered from questionnaire fatigue may not have responded.

Surgical robotic platforms appear to be here to stay. They truly are the alluring, engineering and surgical wonders that are the soul of disruptive change. These devices continue to

improve with each new generation, offering the combination of the master surgeon's judgment and experience with the machines tireless, tremorless reliability, and may offer significant advantages over traditional surgery in the right hands and for the appropriate indications. However, despite these advantages, we have found that HRQoL outcomes do not appear to be significantly different after RARP compared to ORP over the first 15 months postoperatively. Further studies are needed to define in which patient subgroup is robotics likely to significantly advance patient care (improved oncologic outcomes, improved HRQoL) at an acceptable cost. We believe only at that point should new technology be widely introduced.

Conclusion

Although HRQoL was statistically superior after RARP at selected time periods within the first 15 months after surgery, differences were not clinically significant.

Acknowledgements: The paper and our efforts were funded through the generosity of an unrestricted grant of The Weinbaum Family Prostate Cancer Prevention Fund of The Prostate Centre at Princess Margaret Cancer Centre and made possible through the invaluable fund raising and administrative efforts of The Princess Margaret Cancer Centre Foundation. Robin Kalnin of Meridian Software Inc. provided database support.

Competing interests: Ms. Rush, Dr. Alibhai, Dr. L. Xu, Dr. W. Xu, Ms. Louis, Dr. Matthew, Mr. Nesbitt, Dr. Hamilton and Dr. Trachtenberg declare no competing financial or personal interests. Dr. Zlotta is a member of the advisory boards for Amgen, Ferring, and Astellas. He has also received grants from Sanofi, Red Leaf Medical and is currently participating in a clinical trial with Sanofi Aventis. Dr. Kulkarni has received a grant from Astellas and he is currently participating in a clinical trial with Spectrum Pharmaceuticals. Dr. Finelli has participated in clinical trials in the past 2 years for Amgen, Astellas, Janssen and Ferring. He is also Chair of the CUA Guidelines Committee. Dr. Fleshner is a member of the advisory boards for Amgen, Janssen, Astellas and Eli Lilly. He has received honoraria from Amgen, Janssen, Astellas, and Eli Lilly. He is and has participated in clinical trials for Amgen, Janssen, Medivation, OICR, and Prostate Cancer Canada. Dr. Jewett has received grants from, and is participating in clinical trials with Novartis, GSK, and Pfizer.

This paper has been peer-reviewed.

References

1. American Cancer Society. *Cancer Facts & Figures 2014*. Atlanta: American Cancer Society; 2014.
2. Ahlring TE, Woo D, Eichel L, et al. Robot-assisted versus open radical prostatectomy: A comparison of one surgeon's outcomes. *Urology* 2004;63:819-22. <http://dx.doi.org/10.1016/j.urol.2004.01.038>
3. Gettman MT, Blute ML. Critical comparison of laparoscopic, robotic, and open radical prostatectomy: Techniques, outcomes, and cost. *Curr Urol Rep* 2006;7:193-9. <http://dx.doi.org/10.1007/s11934-006-0021-1>
4. Berryhill R Jr, Jhaveri J, Yadav R, et al. Robotic prostatectomy: A review of outcomes compared with laparoscopic and open approaches. *Urology* 2008;72:15-23. <http://dx.doi.org/10.1016/j.urol.2007.12.038>
5. Finkelstein J, Eckersberger E, Sadri H, et al. Open versus laparoscopic versus robot-assisted laparoscopic prostatectomy: The European and US experience. *Rev Urology* 2012;12:35-43.

6. Geraerts I, Van Poppel H, Devoogdt N, et al. Prospective evaluation of urinary incontinence, voiding symptoms and quality of life after open and robot-assisted radical prostatectomy. *BJU Int* 2013;112:936-43. <http://dx.doi.org/10.1111/bju.12258>
7. Krambeck AE, DiMarco DS, Rangel LJ, et al. Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques. *BJU Int* 2009;103:448-53. <http://dx.doi.org/10.1111/j.1464-410X.2008.08012.x>
8. Tewari A, Srivasatava A, Menon M. A prospective comparison of radical retropubic and robot-assisted prostatectomy: Experience in one institution. *BJU Int* 2003;92:205-10. <http://dx.doi.org/10.1046/j.1464-410X.2003.04311.x>
9. Kohn M, Bremner KE, Tomlinson G, et al. Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. *Qual Life Res* 2007;16:509-22. <http://dx.doi.org/10.1007/s11136-006-9132-x>
10. Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. *Int J Impot Res* 1999;11:319-26. <http://dx.doi.org/10.1038/sj.ijir.3900472>
11. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. *J Urol* 1992;148:1549-57. <http://www.ncbi.nlm.nih.gov/pubmed/1279218>
12. Charlson M, Pompei P, Ales K, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *J Chron Dis* 1987;40:373-83. [http://dx.doi.org/10.1016/0021-9681\(87\)90171-8](http://dx.doi.org/10.1016/0021-9681(87)90171-8)
13. Kohn M, Ritvo P, Irvine J, et al. Construction of the patient-oriented prostate utility scale (PORPUS): A multiattribute health state classification system for prostate cancer. *J Clin Epidemiol* 2000;53:920-30. [http://dx.doi.org/10.1016/S0895-4356\(00\)00211-0](http://dx.doi.org/10.1016/S0895-4356(00)00211-0)
14. Ritvo P, Irvine J, Naglie G, et al. Reliability and validity of the PORPUS, a combined psychometric and utility-based quality-of-life instrument for prostate cancer. *J Clin Epidemiol* 2005;58:466-74. <http://dx.doi.org/10.1016/j.jclinepi.2004.08.019>
15. O'Connor RC, Bales GT, Avila D, et al. Variability of the International Prostate Symptom Score in men with lower urinary tract symptoms. *Scand J Urol Nephrol* 2003;37:35-7. <http://dx.doi.org/10.1080/00365590310008668>
16. Rosen RC, Allen KR, Ni X, et al. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function Scale. *Eur Urol* 2011;60:e37-48.
17. Ringash J, O'Sullivan B, Bezjak A, et al. Interpreting clinically significant changes in patient-reported outcomes. *Cancer* 2007;110:196-202. <http://dx.doi.org/10.1002/cncr.22799>
18. Walsh PC, Mostwin JL. Radical prostatectomy and cystoprostatectomy with preservation of potency: Results using a new nerve-sparing technique. *Br J Urol* 1984;56:694-7. <http://dx.doi.org/10.1111/j.1464-410X.1984.tb06149.x>
19. Menon M, Tewari A, Peabody J; VIP Team. Vattikuti Institute prostatectomy: Technique. *J Urol* 2003;169:2289-92. <http://dx.doi.org/10.1097/01.ju.0000067464.53313.dd>
20. Ficarra V, Novara G, Artibani W, et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: A systematic review and cumulative analysis of comparative studies. *Eur Urol* 2009;55:1037-63. <http://dx.doi.org/10.1016/j.eururo.2009.01.036>
21. Barry MJ, Gallagher PM, Skinner JS, et al. Adverse effects of robotic-assisted laparoscopic versus open retropubic radical prostatectomy among a nationwide random sample of medicare-age men. *J Clin Oncol* 2012;30:513-8. <http://dx.doi.org/10.1200/JCO.2011.36.8621>
22. Schroeck FR, Krupski TL, Sun L, et al. Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. *Eur Urol* 2008;54:785-93. <http://dx.doi.org/10.1016/j.eururo.2008.06.063>

Correspondence: Dr. John Trachtenberg, Department of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the Department of Surgery, University of Toronto, Toronto, ON, john.trachtenberg@uhn.ca

Appendix. The Prostate-Oriented Record of Psychometric and Utility-Based Outcomes Scale

I. Pain and disturbing body sensations

1. No pain and disturbing body sensations.
2. Mild pain or disturbing body sensation that does not limit any activities (e.g., work, social, sexual, sleep).
3. Moderate pain or disturbing body sensations that limits a few activities.
4. Moderate to severe pain or disturbing body sensations that limits many activities.

II. Energy

1. Very full of energy, lots of pep.
2. Fairly energetic, no limitation of activities (e.g., work, social, sexual).
3. Moderate reduction in energy or pep that limits some activities.
4. Generally low energy or pep that limits some activities.
5. No energy or pep at all. I feel drained, and many activities are limited.

III. Support from family and friends

1. Most of the time feel supported by my spouse, family, and friends.
2. A fair amount of the time feel supported by my spouse, family, and friends.
3. Occasionally feel supported by my spouse, family, and friends.
4. Rarely feel supported by my spouse, family, and friends.

IV. Communication with doctor (primary caregiver for prostate cancer, may be specialist or family doctor)

1. Always able to express my concerns to my doctor and get all the information or advice I need.
2. Most of the time, able to express my concerns to my doctor and get all the information or advice I need.
3. Some of the time, able to express my concerns to my doctor and get all the information or advice I need.
4. Rarely able to express my concerns to my doctor and get all the information or advice I need.

V. Emotional well-being

1. Generally happy and free from worry, sadness, or frustration.
2. A little worry, sadness, or frustration.
3. Moderate worry, sadness, or frustration.
4. Quite a bit of worry, sadness, or frustration.
5. Extreme worry, sadness, or frustration.

VI. Urinary frequency (need to pass urine frequently during the day or night) and urgency (difficulty delaying urination after the urge is felt to urinate and ability to "hold it")

1. No urinary frequency or urgency.
2. A little urinary frequency or urgency, does not interfere with sleep or other activities (e.g., work, social),
3. Some urinary frequency or urgency that interferes with sleep or other activities, may need to plan ahead.
4. Quite a bit of urinary frequency or urgency, need to be near a bathroom most of the time.
5. Extreme urinary frequency or urgency, need to be near a bathroom always.

VII. Leaking urine/poor bladder control

1. Never, under any circumstances leak urine or lose bladder control.
2. On rare occasions, leak urine or lose bladder control, does not interfere with any activities (e.g., work, social, sexual, sleep).
3. Occasionally leak urine or lose bladder control, interferes with a few activities.
4. A moderate amount of the time, leak urine or lose bladder control, interferes with some activities.
5. Most of the time, leak urine or have poor bladder control, interferes with many activities.
6. Require a clamp, catheter, or collecting bag, because leaking urine or poor bladder control.

VIII. Sexual function (problems with achieving/maintaining an erection)

1. Full erections sufficient for intercourse.
2. Erections sufficient for intercourse, but some reduction in firmness.
3. Erections sufficient for masturbation or foreplay only.
4. Erections, but not firm enough for any sexual activity.
5. No erections at all.

IX. Sexual interest/drive

1. Normal amount of sexual drive and interest for you.
2. A little decrease of sexual drive or interest for you.
3. Moderate decrease of sexual drive or interest for you.
4. Substantial decrease of sexual drive or interest for you.
5. No sexual drive or interest.

X. Bowel problems: diarrhea, rectal discomfort (pain, burning or irritation), or constipation

1. No diarrhea, rectal discomfort, or constipation.
2. Occasionally have diarrhea, rectal discomfort, or constipation.
3. Frequently have diarrhea, rectal discomfort, or constipation.
4. Nearly always have diarrhea, rectal discomfort, or constipation.

Taken from Ku et al. *Can Urol Assoc J* 2009;3(6):445-52.